Arcus Bios Reports Casdatifan Data Across ccRCC Treatment Lines
Arcus Bios presented updated ARC-20 data showing promising efficacy and manageable safety in first-, second- and late-line ccRCC settings. The headline reports a 50% first-line cORR.
Arcus Bios presented updated ARC-20 data showing promising efficacy and manageable safety in first-, second- and late-line ccRCC settings. The headline reports a 50% first-line cORR.